ClinicalTrials.gg
CompletedNCT00390702pfm-01/2005Updated Nov 7, 2018

Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System

An interventional study of transcatheter implantation of a VSD occluder (Nitinol coil) in Heart Septal Defects, Ventricular, sponsored by pfm medical gmbh. Completed at 6 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2018-11-07.

Sponsored by pfm medical gmbh · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
103
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Study summary

The Ventricular septal defect (VSD) is the most common of all congenital cardiac malformations. By modifying the Nit-Occlud® PDA Device the Nit-Occlud® Lê VSD Spiral System was designed. as a percutaneous, transcatheter device for occlusion of (peri)membranous and muscular ventricular septum defects (VSD) with a spiral coil. In this clinical investigation feasibility, safety and performance of the new cardiac occluder will be evaluated in accordance with European and US regulations. The study data will be compared to performance criteria for VSD, which are deduced analogue to the published specific Objective Performance Criteria (OPCs) for PDAs. The first part of the study has been performed in three clinical centres in Germany. For the second part in April 2009 four additional clinical centres in Germany, Israel, Italy and Spain were included.

02

Conditions studied

  • Heart Septal Defects, Ventricular

Keywords

  • Ventricular septal defect
  • VSD
03

In context

Heart Septal Defects, Ventricular

59 studies on the registry are indexed under Heart Septal Defects, Ventricular; 9 are open to participants now.

This study's enrollment of 103 is above the median of 86 across 29 interventional studies indexed under Heart Septal Defects, Ventricular.

Browse Heart Septal Defects, Ventricular studies →

Lead sponsor

pfm medical gmbh is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • VSD must be diagnosed by acknowledged methods, like echocardiography
  • Signs of left ventricular volume overload are present (left ventricle or left atrium diameters 2 standard deviations greater than normal) and/or measured by catheterisation : Qp/Qs > 1.5
  • Pulmonary vascular resistance is less than 4 Wood units
  • The patient is older than 24 months
  • The VSD has a perimembranous or muscular location.
  • A distance between the rim of the VSD and the aortic annulus of at least 3.0 mm (as measured on the 2-D echocardiography - apical 5-chamber view)
  • The minimal diameter (size) of the VSD is less than 8.0 mm (as measured on the 2-D echocardiography - apical 5-chamber view)
  • Patient must agree to fully participate in the clinical trial and give in writing. If the patient is without legal ability additionally the person of legal responsibility must agree and s/he must give the informed consent in writing

Exclusion criteria

Exclusion Criteria:

Pathological or physical condition precluding the implantation of a Nit-Occlud® Lê VSD coil, such as :

  • perimembranous VSD with no evidence of circular aneurysm formation
  • Associated cardiac anomalies requiring surgery (greater than mild aortic insufficiency; such as aortic valve prolapse)
  • Active endocarditis or other type of sepsis or other active infection at time of implantation
  • Thrombus at or near the intended site of implantation
  • Thrombus in the vessels through which access to the VSD is gained (unless the patient is protected with an embolic protection device such as a vena cava filter)
  • Vessels through which access to the VSD is gained can not accommodate a 7 F sheath
  • Potential steric (3-dimensional) interference of the occluder with intracardiac or intravascular structures (like valves)
  • History of blood disorder (coagulopathy, tendency towards haemolysis)
  • History of to contrast medium or Nitinol
  • AV-block II° or III°, atrial fibrillation, or atrial flutter
  • End stage cardiac disease, irreversible major organ failure, or terminal cancer
  • infection
  • Cerebrovascular disease or neurological deterioration
  • Emergency cardiologic intervention
  • Patient*) is not able to fully participate in this study including all follow-ups (e.g. for mental or geographical reasons, or patient is intravenous drug user or has strong potential for non-compliance to medical regimes)
  • Patient, respectively the person of legal responsibility, is mentally unable to understand the nature, aims, or possible consequences of the clinical investigation
  • Pregnant or breast-feeding women
  • Patient did participate in another clinical investigation during the last 3 months
  • Patient or the person of responsibility has revoked the consent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    VSD occluder

    transcatheter implantation of a VSD occluder (Nitinol coil)

    Device: transcatheter implantation of a VSD occluder (Nitinol coil)

Interventions

  • Devicetranscatheter implantation of a VSD occluder (Nitinol coil)

    transcatheter implantation, by first performing a arterial-venous loop through the defect

    Also known as: Nit-Occlud® Lê VSD Occluder

06

What researchers measure

Primary outcomes

  1. a set of Performance Criteria (PC) deduced for VSD analogue to the set of Objective Performance Criteria (OPC) of the 'Multiorganization Advisory Panel to FDA for Pediatric Cardiovascular Devices' for PDAs

    Time frame: Five years

07

Study locations

6 sites
  • Dept. Congem.Heart Defects, Deutsches Herzzentrum
    Berlin, 13353, Germany
  • Cardio-Vascular Centre, Sankt Kathrinen
    Frankfurt, 60389, Germany
  • Univ.Klinikum, Zentrum fuer Kinderheilkunde
    Giessen, 35390, Germany
  • Dept. Paediatric Cardiology, Univ. Hospital Hamburg
    Hamburg, 20246, Germany
  • Dept. Paediatric Cardiology, Univ. Clinic Grosshadern
    Munich, 81377, Germany
  • Meyer Children's Hospital, Rambam Med. Center
    Haifa, 31096, Israel
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2006 to primary completion in Aug 2012, 70 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2006
First posted
Oct 20, 2006
StartActual
Oct 2006
Primary completionActual
Aug 2012
CompletionActual
May 2017
Last update
Nov 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00390702
Lead sponsor
pfm medical gmbh
Collaborators
Aix Scientifics
Responsible party
Sponsor
First posted
Oct 20, 2006
Start date
Oct 2006
Primary completion
Aug 2012
Completion
May 2017
Last update
Nov 7, 2018

Study contacts

Thomas Meinertz, Prof Dr med
principal investigator · University Hospital Hamburg Eppendorf, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion